drugset / Trial / NCT03761225
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2014-09
- Primary completion
- 2020-12-15
- Completion
- 2020-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | — | — |